(Arg)9 acetate Nona-L-arginine acetate; Peptide R9 acetate|西域试剂

(Arg)9 acetate Nona-L-arginine acetate; Peptide R9 acetate,99.12%

产品编号：Bellancom-P0133B| 分子式：C₅₆H₁₁₄N₃₆O₁₂| 分子量：1483.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P0133B	￥1200.00	杭州北京（现货）
Bellancom-P0133B	￥3850.00	杭州北京（现货）
Bellancom-P0133B	￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

(Arg)9 acetate Nona-L-arginine acetate; Peptide R9 acetate

产品介绍

(Arg)9 (Nona-L-arginine) acetate 是一种由 9 个精氨酸残基组成的细胞穿透肽 (CPP)。(Arg)9 acetate 具有神经保护功能，在谷氨酸模型中 IC₅₀ 值为 0.78 μM。

生物活性

(Arg)9 (Nona-L-arginine) acetate is a cell-penetrating peptide (CPP) made up of 9 arginine residues. (Arg)9 acetate has neuroprotective property, exhibits neuroprotective activity with an IC₅₀ of 0.78 μM in the glutamic acid model.

体外研究

(Arg)9 (Nona-L-arginine; 5-10 μM) acetate provides significant neuroprotection in a dose–response manner following glutamic acid exposure (IC₅₀=0.78 μM). Following kainic acid exposure, (Arg)9 acetate is neuroprotective, but less effective than in the glutamic acid model (IC₅₀=0.81 μM). (Arg)9 acetate also shows neuroprotection following in vitro ischemia (IC₅₀=6 μM).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

(Arg)9 (Nona-L-arginine; 1 μM/kg (600 μL); i.v.; once, for 30min; male Sprague–Dawley ratspermanent middle cerebral artery stroke model) acetate shows neuroprotective effects and reduces infarct volume.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model
Dosage:	1 μM/kg (600 μL)
Administration:	Intravenous injection; once, over 5 minutes
Result:	Reduced significantiy 20% in infarct volume.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague–Dawley rats (270 to 320 g) permanent middle cerebral artery stroke model
Dosage:	1 μM/kg (600 μL)
Administration:	Intravenous injection; once, over 5 minutes
Result:	Reduced significantiy 20% in infarct volume.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (67.40 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.6740 mL	3.3699 mL	6.7397 mL
5 mM	0.1348 mL	0.6740 mL	1.3479 mL
10 mM	0.0674 mL	0.3370 mL	0.6740 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶